What is the best treatment for patients with human papillomavirus-positive and -negative oropharyngeal cancer? (Q27026269)

language of work or name

1 reference

15 May 2014

1 reference

1 reference

120

1 reference

issue

10

1 reference

page(s)

1462-70

1 reference

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Prevalence of oral HPV infection in the United States, 2009-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Case-control study of human papillomavirus and oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

The molecular biology of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

The mutational landscape of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

HPV detection methods in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Tumour boards/multidisciplinary head and neck cancer meetings: are they of value to patients, treating staff or a political additional drain on healthcare resources?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Reduced lung-cancer mortality with low-dose computed tomographic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

Trends in premarital sex in the United States, 1954-2003

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

Is radiation therapy a preferred alternative to surgery for squamous cell carcinoma of the base of tongue?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

Reducing posttreatment dysphagia: Support for the relationship between radiation dose to the pharyngeal constrictors and swallowing outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28595

7 January 2021

Identifiers

DOI

10.1002/CNCR.28595

0 references

PubMed publication ID

24578320

1 reference